Reviews ibogaine's potential for Parkinson's and related neurological conditions.
Ibogaine increases GDNF as a potential trophic strategy for PD.
Ibogaine's GDNF upregulation may protect dopaminergic neurons in Parkinson's.
Low-dose ibogaine improved motor symptoms, quality of life, and depression in a PD patient.
Ibogaine analogs show promise for neurological disorders via neurotrophic stimulation.
Overview notes ibogaine's potential in neuropsychiatric conditions, with MS motor considerations.
Ibogaine and psychedelics reduce neuroinflammation and support repair in MS.
Ibogaine promotes remyelination and neuroplasticity relevant to MS via multi-receptor actions.
Two MS patients showed ~71% reduction in white matter lesions and symptom relief after ibogaine.
In 33 cases, 76% showed resolution of opioid withdrawal within 24 hours.
User interviews highlight psychological insights and addiction interruption in underground settings.
Clinical data show single-dose ibogaine diminishes withdrawal and cravings in opioid/cocaine users.
Reviews ibogaine's role in addiction interruption, supported by pilot studies and progression to trials.
Review of 24 studies (705 individuals) notes ibogaine reduces withdrawal/craving in SUDs but highlights risks like cardiotoxicity.
Ibogaine significantly reduced withdrawal and opioid use at 1-12 months in subjects with prior treatment failures.
Survey of patients showed reductions in opioid use, abstinence in some, and long-term improvements in mood and cravings.
Single ibogaine treatment reduced opioid withdrawal and led to sustained cessation or reduced use over 12 months in most participants.
